U.S. Specialty Stores Stock News

Worthington Steel recently filed its latest Form 10-Q, showing growth supported by stronger automotive demand and the completed acquisition of Sitem Group, which expands its European footprint and production capabilities. An interesting takeaway is how the Sitem acquisition deepens Worthington Steel’s role in supplying automotive customers in Europe, potentially reshaping its geographic and product mix. We’ll now examine how the Sitem-driven European expansion highlighted in the 10-Q could...

Incyte (INCY) is back in focus after reporting positive Phase 3 frontMIND trial results for tafasitamab plus lenalidomide and R-CHOP in first-line diffuse large B-cell lymphoma, with plans for an expanded filing in 2026. See our latest analysis for Incyte. The frontMIND update comes after a strong run in the shares, with a 30 day share price return of 12.29% and a 90 day share price return of 27.53%, while the 1 year total shareholder return of 51.50% points to momentum building around...

In recent days, GXO Logistics has drawn attention as multiple research firms reiterated positive views on the company while it reshaped its leadership team, including appointing Bomber as Chief Commercial Officer amid reports of increased insider share purchases. Together, upbeat analyst sentiment and insider buying hint that those closest to the business see management changes as important for GXO’s long-term direction. Next, we’ll explore how growing analyst enthusiasm toward GXO’s...

Crocodile Capital Partners’ new US$41 million position in Alpha Metallurgical Resources (AMR), now the fund’s second largest holding, has drawn fresh attention to the stock alongside recent insider purchases and coal demand projections. See our latest analysis for Alpha Metallurgical Resources. Those fund inflows and insider purchases arrive as momentum in Alpha Metallurgical Resources has picked up sharply, with a 35.41% 1 month share price return feeding into a 51.43% 3 month share price...

Simpson Manufacturing recently announced that CEO Mike Olosky and CFO Matt Dunn participated virtually in the CJS Securities 26th Annual New Ideas for the New Year Conference on January 14, 2026, with their presentation webcast on the company’s Investor Relations site and available for replay. At the same time, fresh analysis pointing to slower revenue growth, declining EPS, and weaker returns on invested capital has raised questions about the strength of Simpson’s underlying business...

In recent days, Sphere Entertainment received an upgrade from Seaport Global from Neutral to Buy, following a series of earlier positive analyst views tied to venue performance, sponsorship activity, and attendance trends. At the same time, Sphere’s fundamentals remain mixed, with weak long-term sales growth and constrained free cash flow raising questions about how effectively it can reinvest behind its high-profile partnerships and expanding venue platform. We’ll now explore how Seaport...

Paymentus Holdings (PAY) is back on traders’ screens after a sharp move in its share price, as the company reaffirmed its full year outlook and highlighted fresh integrations across utilities, municipalities, healthcare, and government clients. See our latest analysis for Paymentus Holdings. The latest reaffirmed outlook and new client integrations come after a mixed stretch for the stock, with a 7 day share price return of 6.5%, a 30 day share price return of 12.92%, and a flat 90 day move...

Collegium Pharmaceutical (COLL) shares are reacting to fresh 2026 guidance, with management projecting US$805 million to US$825 million in net product revenue and outlining plans tied to Jornay PM and growth in its pain portfolio. See our latest analysis for Collegium Pharmaceutical. The fresh 2026 guidance and new Nucynta authorized generic agreements arrive after a sharp 42.13% 90 day share price return and a 38.38% one year total shareholder return, even with the recent 6.79% one month...

Rhythm Pharmaceuticals (RYTM) is back in focus after issuing preliminary 2025 guidance, highlighting IMCIVREE revenue estimates and upcoming trial milestones that could influence how investors think about the company’s rare disease franchise. See our latest analysis for Rhythm Pharmaceuticals. Rhythm’s share price has been volatile around the guidance, with a 3.65% 1 day share price return contrasting with a 7 day share price return of negative 3.80%, while the 1 year total shareholder return...

In early January 2026, Valens Semiconductor announced its fourth global MIPI A-PHY design win, with VA7000 chipsets set to power ADAS connectivity for a premium global automotive OEM serving the Chinese market, alongside unveiling the automotive industry's first production-ready MIPI A-PHY-enabled e-mirror developed with Sakae Riken Kogyo in Japan. These developments highlight growing ecosystem adoption of the MIPI A-PHY standard and underline Valens' role in enabling high-bandwidth sensor...

Rush Street Interactive (RSI) has been in focus after its third quarter 2025 results topped analyst expectations for both earnings per share and revenue, putting recent insider trading activity in a different context for investors. See our latest analysis for Rush Street Interactive. At a share price of $19.26, Rush Street Interactive has seen a 4.9% 90 day share price return, while its 1 year total shareholder return of 37.77% and very large 3 year total shareholder return around 4.7x...

Broadridge Financial Solutions recently expanded its partnership with Utah-based agentic AI firm DeepSee, taking a minority ownership stake and rolling out AI-powered email orchestration to automate post-trade workflows already used across its Business Process Outsourcing Operations serving over 60 clients. This move highlights Broadridge’s push to embed industry-specific AI agents directly into post-trade communications, turning unstructured email into actionable workflows that link...

Clearway Energy Operating LLC, a subsidiary of Clearway Energy, Inc., recently priced an upsized US$600,000,000 offering of 5.750% senior unsecured notes due 2034, guaranteed by Clearway Energy LLC and its wholly owned subsidiaries, with proceeds earmarked to refinance debt and support renewable generation and storage assets. This larger green-focused debt raise highlights how Clearway is using bond markets to reshape its balance sheet while expanding its clean energy footprint. Next, we’ll...

PagSeguro Digital (PAGS) has announced new income for shareholders, with its Board approving a special cash dividend of US$0.12 per common share, scheduled for payment on February 27, 2026. See our latest analysis for PagSeguro Digital. PagSeguro Digital's recent special dividend decision comes after a period of firmer trading, with a 90-day share price return of 17.60% and a 1-year total shareholder return of 68.89%, signaling building momentum from a much weaker 5-year total shareholder...

Acuity (AYI) is back in focus after its latest fiscal first quarter, where earnings topped expectations and revenue grew more than 20% year on year, helped by its Intelligent Spaces business. See our latest analysis for Acuity. The strong fiscal first quarter has not stopped near term pressure, with a 7 day share price return of a 12.8% decline and a 30 day share price return of a 12.6% decline. Total shareholder return sits at 6.9% over one year and almost 1.8x over five years. Recent...

Bright Horizons Family Solutions recently reported very strong earnings momentum, with earnings per share rising sharply over the past year and across the last three years, alongside analyst forecasts for earnings to grow faster than the broader market over the next three years. This alignment between recent earnings strength and expectations for continued outperformance helps explain why investors appear comfortable with the company’s relatively high earnings multiple. We’ll now examine how...

On 7 January 2026, CareDx announced a collaboration with 10x Genomics to create ImmuneScape, a multiomics initiative using 10x’s Xenium spatial and Chromium Flex single-cell platforms to study transplant organ rejection and therapeutic response. This program aims to generate high-resolution immune maps from FFPE biopsy samples, potentially informing future transplant diagnostics and more personalized treatment selection. We’ll now examine how this ImmuneScape collaboration, centered on 10x’s...

ANI Pharmaceuticals (ANIP) is back in focus after robust 2025 results, with sales and earnings outperforming expectations and management raising full year guidance, which is putting fresh attention on how its rare disease portfolio is shaping the stock. See our latest analysis for ANI Pharmaceuticals. The latest results arrive after a softer patch for the shares, with a 1-day share price return of a 5.87% decline and a 90-day share price return of a 15.05% decline. This comes even as the...

In recent days, Qfin Holdings has come under pressure as China fintech American depositary receipts reacted to U.S. tariff uncertainty and concerns around China's consumer credit conditions, following regulators' decision to extend programs targeting bad personal loans. This environment highlights how Qfin's AI-driven credit platform could be tested by shifting regulatory priorities and efforts to stabilize household borrowing. Next, we’ll examine how extended bad-loan programs and cautious...

Regulatory moves put Eversource Energy (ES) under closer investor scrutiny Eversource Energy (ES) is back in focus after Connecticut regulators rejected its planned sale of a water utility business, and its NStar Gas unit reached a rate settlement with the Massachusetts Attorney General. See our latest analysis for Eversource Energy. These regulatory twists seem to be weighing on sentiment in the short term, with a 90 day share price return showing a 6.3% decline and year to date share price...

If you are wondering whether Bank of N.T. Butterfield & Son at around US$50.36 is priced attractively or not, the key question is how that share price stacks up against its underlying value. The stock has returned 1.3% over the last 7 days, 0.0% over the past 30 days and 1.3% year to date, while the 1 year and 3 year returns sit at 49.8% and 87.7% respectively. This makes the current level especially interesting for anyone thinking about risk and reward. Recent trading interest has been...

In 2025, Twist Bioscience’s CEO and Chair Emily M. Leproust received total compensation of US$13,781,570, while recent insider activity showed only stock sales and no purchases alongside adjustments in institutional holdings. At the same time, multiple brokerage firms reiterated positive views on Twist Bioscience’s semiconductor-based DNA synthesis platform, collectively maintaining an “Outperform” stance backed by confidence in its synthetic biology technology. Building on this renewed...

Capricor Therapeutics recently reported that its Phase 3 trial of deramiocel met both primary and secondary endpoints and entered commercialization and distribution agreements with Nippon Shinyaku covering the U.S., Japan, and Europe, with potential milestones totalling US$1.50 billion. This combination of late-stage clinical success and a broad global partnership materially advances Capricor’s path from a purely clinical-stage company toward potential commercial execution. We’ll now examine...

If you are wondering whether Wendy's current share price reflects good value or lingering concerns, this breakdown is designed to help you connect the dots before you make your own call. The stock closed at US$8.65, with returns of 5.9% over the past week and 5.7% over the past month, while the 1 year return of a 38.6% decline and 3 year and 5 year returns of 55.9% and 50.8% declines tell a different story about longer term sentiment. Recent headlines around Wendy's have focused on how the...